Investor Presentaiton
40
Investor presentation
Full year 2022
The total branded diabetes market has a global value of DKK
~365 billion annually
DKK
billion
Global diabetes market
DKK
The USA
billion
+16%
+17%
400
367
2021/2022 2020/2021 Growth at CER
200
177
141
150
+34%
-12%
90
302
300
100
64
+1%
40 42
50
+35%
31
16 14
20
0
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
200
DKK
Outside the USA
+39%
billion
+14%
-6%
190
130
200
109 112
161
+41%
100
90
-2%
150
-3%
72
56 53
100
47
69 70
+51%
40
-2%
40 39
+46%
41
50
26
26
0
Total
0
Insulin
GLP-1
DPP-4i
SGLT-2i
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
Source: Company announcements as of Q3 2022; 2021/2022 data based on Q4 2021 to Q3 2022 and 2020/2021 data based on Q4 2020 to Q3 2021
Note: The segment value is based on reported figures, whilst the market growth is under constant exchange rate (CER). For Novo Nordisk the diabetes growth includes Insulin and GLP-1, excluding 'other Diabetes care'.
Novo NordiskⓇView entire presentation